Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 80 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prodromal Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension

NCT04937959
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Mild Cognitive Impairment, Normal Cognition
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 31, 2026, 9:49 AM EDT
Active, not recruiting Phase 2 Interventional

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

NCT05686551
View directory record Official record
Conditions
Huntington Disease
Interventions
Tominersen, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years to 50 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 31, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

NCT02640092
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
[18F]GTP1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
16
States / cities
New Haven, Connecticut • Stamford, Connecticut • Fort Myers, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 31, 2026, 9:49 AM EDT
Completed Phase 2 Interventional Results available

Ziprasidone in the Psychosis Prodrome

NCT00635700
View directory record Official record
Conditions
Psychosis Prodrome
Interventions
ziprasidone, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
16 Years to 40 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 31, 2026, 9:49 AM EDT
Withdrawn Not applicable Interventional

HOPE TEAM - Clinical High Risk Group CBSST

NCT03738046
View directory record Official record
Conditions
Prodromal Symptoms, Prodromal Stage, Prodromal States, Psychosis
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
13 Years to 19 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 31, 2026, 9:49 AM EDT
Completed Phase 2 Interventional

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

NCT01141023
View directory record Official record
Conditions
Parkinson Disease
Interventions
DaTscan
Drug
Lead sponsor
Ken Marek, MD
Other
Eligibility
30 Years and older
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
21
States / cities
Birmingham, Alabama • Sun City, Arizona • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 31, 2026, 9:49 AM EDT
Completed Phase 3 Interventional Results available

A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease

NCT01224106
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 31, 2026, 9:49 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

TMS in Preclinical and Prodromal AD: Modulation of Brain Networks and Memory

NCT04294888
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Aging
Interventions
repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 31, 2026, 9:49 AM EDT
Recruiting Phase 2 Interventional

Alzheimer's Tau Platform: Master Protocol

NCT06957418
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
Interventions
AADvac1, Tau2
Drug
Lead sponsor
Paul S. Aisen
Other
Eligibility
50 Years to 80 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Phoenix, Arizona • San Francisco, California • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 9:49 AM EDT
Completed Phase 2 Interventional

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi

NCT02481674
View directory record Official record
Conditions
Huntington's Disease
Interventions
VX15/2503, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
21 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
29
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 31, 2026, 9:49 AM EDT
Completed Not applicable Interventional

Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease

NCT04029623
View directory record Official record
Conditions
Prodromal Alzheimer's Disease
Interventions
Partnered Rhythmic Rehabilitation (PRR), Group walking (WALK)
Other
Lead sponsor
Emory University
Other
Eligibility
50 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 31, 2026, 9:49 AM EDT
Terminated Phase 1 Interventional

Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

NCT01677572
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 90 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
32
States / cities
Tucson, Arizona • Laguna Hills, California • Lomita, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 31, 2026, 9:49 AM EDT
Completed No phase listed Observational

Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy

NCT02155595
View directory record Official record
Conditions
Osteoporosis, Atypical Femoral Fractures, Prodromal Bone Deterioration
Interventions
500 without BP treatment, 500 with BP treatment
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
50 Years and older · Female only
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 31, 2026, 9:49 AM EDT
Completed Phase 1 Interventional

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

NCT04566003
View directory record Official record
Conditions
Alzheimer Disease (AD)
Interventions
[18F]GTP1, [18F]PI-2620, [18F]MK-6240
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 31, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Results available

NAPLS Omega-3 Fatty Acid Versus Placebo Study

NCT01429454
View directory record Official record
Conditions
Psychosis
Interventions
Omega-3 Long Chain Fatty Acid, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
12 Years to 30 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 31, 2026, 9:49 AM EDT
Withdrawn Phase 2 Interventional

Clinical Trial of AGB101 for Mild Cognitive Impairment

NCT05986721
View directory record Official record
Conditions
Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Interventions
AGB101, Placebo
Drug
Lead sponsor
AgeneBio
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 31, 2026, 9:49 AM EDT
Completed Not applicable Interventional

Neurofeedback Training for High Risk Psychosis

NCT03447548
View directory record Official record
Conditions
Prodromal Schizophrenia
Interventions
Neurofeedback processing speed training, Active control
Behavioral
Lead sponsor
Hartford Hospital
Other
Eligibility
12 Years to 25 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 31, 2026, 9:49 AM EDT
Terminated Phase 3 Interventional Results available

A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease

NCT02956486
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Elenbecestat, Placebo
Drug
Lead sponsor
Eisai Co., Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
2,212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
88
States / cities
Chandler, Arizona • Colton, California • Costa Mesa, California + 68 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 31, 2026, 9:49 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

NCT03444870
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
33
States / cities
Tucson, Arizona • Irvine, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 31, 2026, 9:49 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

GBPDC: Gut-Brain in PD Consortium Master Protocol

NCT07567794
View directory record Official record
Conditions
Parkinson Disease (PD), PARKINSON DISEASE (Disorder), Gut Microbiome, Gut Microbiota, Prodromal Parkinsons Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
21 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
7
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 9:49 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Parkinson's Disease in Type 1 Gaucher Disease

NCT07886879
View directory record Official record
Conditions
Parkinson Disease (PD), Type 1 Gaucher Disease
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 31, 2026, 9:49 AM EDT
Recruiting Not applicable Interventional

Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk

NCT05131035
View directory record Official record
Conditions
Psychosis, Prodromal Schizophrenia, Prodromal Symptoms
Interventions
SCORES (Specific COgnitive Remediation with Support)
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
14 Years to 20 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 31, 2026, 9:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping

NCT04928976
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 31, 2026, 9:49 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

NCT03887455
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
Lecanemab IV, Placebo, Lecanemab SC
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
112
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 9:49 AM EDT